Máj- és epeúti rák: vizsgálatok itt: Tajvan
54 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleVisugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- Where
- Chiayi City, Taipei
- Életkor
- 18 év to 100 év
- People
- 104 worldwide
- Run by
- CatalYm GmbH
See details and how to joinNCT07219459 · EU 2025-520675-86-00 - 3. fázisTaking peopleD07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
- Where
- Kaohsiung City
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- InnoPharmax Inc.
See details and how to joinNCT06622057 - 2. fázisNot yet taking people in TajvanDaraxonrasib in Asian RAS-mutant Biliary Tract Cancer
- Where
- Kaohsiung City
- Életkor
- 18 év and over
- People
- 55
- Run by
- National Health Research Institutes, Taiwan
See details and how to joinNCT07908550 - 1/2. fázisTaking peopleA Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- Where
- Taichung, Tainan, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06428409 · EU 2023-508703-21-00 - 2. fázisTaking peopleDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Taipei
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - No phaseTaking peopleObservational Study Protocol: LIVER-R
- Where
- Kaohsiung City, Taichung, Taipei, Taoyuan City
- Életkor
- 18 év to 130 év
- People
- 4000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06252753 - 3. fázisTaking peopleEfficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Where
- Kaohsiung City, Tainan, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 286 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT06282575 · EU 2023-508219-21-00 - 2. fázisNot yet taking people in TajvanAn Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC
- Where
- Hsinchu, Taipei
- Életkor
- 18 év and over
- People
- 40
- Run by
- National Taiwan University Hospital
See details and how to joinNCT07902258 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Taichung, Tainan, Taipei
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 1/2. fázisTaking peopleA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Where
- Taichung, Tainan, Taipei
- Életkor
- 18 év and over
- People
- 198 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07291076 · EU 2025-523602-33-00 - 1/2. fázisTaking peopleA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Where
- Kaohsiung City, New Taipei City, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 862 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05914116 - 1. fázisTaking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Kaohsiung City, Taichung, Taipei, Taoyuan City
- Életkor
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - 1/2. fázisTaking peopleFirst in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Where
- Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 304 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06795022 · EU 2024-516698-56-00 - 1. fázisTaking peopleSafety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- Where
- Taipei
- Életkor
- 18 év and over
- People
- 125 worldwide
- Run by
- Tyra Biosciences, Inc
See details and how to joinNCT06915753 - 3. fázisTaking peoplePhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Where
- Kaohsiung City, Taichung, Taipei, Taoyuan
- Életkor
- 18 év to 99 év
- People
- 620 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06467357 · EU 2023-508057-19-00 - 3. fázisTaking peoplePhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Where
- Changhua, Kaohsiung City, Taichung, Tainan, Tainan County, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 1220 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06921785 · EU 2024-518210-81-00 - 1/2. fázisTaking peopleSymbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Where
- Taichung, Tainan, Taipei
- Életkor
- 18 év and over
- People
- 138 worldwide
- Run by
- Pfizer
See details and how to joinNCT07227012 · EU 2025-523525-17-00 - 1. fázisTaking peopleA Study of ZW251 in Participants With Advanced Solid Tumors
- Where
- Taipei
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Zymeworks BC Inc.
See details and how to joinNCT07164313 - 2. fázisTaking peopleAtezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
- Where
- Taoyuan City
- Életkor
- 18 év and over
- People
- 45
- Run by
- Chang Gung Memorial Hospital
See details and how to joinNCT06339424 - No phaseTaking peopleEvaluation of Immune Responses and Outcomes in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy
- Where
- Taoyuan City
- Életkor
- 18 év and over
- People
- 300
- Run by
- Chang Gung Memorial Hospital
See details and how to joinNCT06379256 - 2. fázisTaking peopleProton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
- Where
- Taoyuan City
- Életkor
- 18 év and over
- People
- 45
- Run by
- Chang Gung Memorial Hospital
See details and how to joinNCT06999694 - 2. fázisTaking peoplePhoton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
- Where
- Taoyuan City
- Életkor
- 18 év and over
- People
- 45
- Run by
- Chang Gung Memorial Hospital
See details and how to joinNCT06999707 - 2. fázisTaking peopleAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Where
- Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 226 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06219941 · EU 2023-508275-37-00 - 2. fázisTaking peopleHyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab
- Where
- Taoyuan City
- Életkor
- 18 év and over
- People
- 45
- Run by
- Chang Gung Memorial Hospital
See details and how to joinNCT06605664 - 3. fázisTaking peopleA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Where
- Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
- Életkor
- 18 év and over
- People
- 1100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07221253 · EU 2025-523085-24-00